Use of recombinant factor VILa in Operation Iraqi Freedom and Operation Enduring Freedom: survey of Army surgeons.
Military physicians are using recombinant factor VIIa (rFVIIa) in Iraq and Afghanistan to help stop life-threatening hemorrhage in trauma patients. We constructed a questionnaire and surveyed Army general surgeons deployed to Iraq and/or Afghanistan about their predeployment experience, deployment experience, and projected postdeployment practice regarding rFVIIa usage. Most surgeons had rFVIIa available during their deployment (65%). The drug was used with varying frequency and subjective therapeutic effect. A majority of surgeons (79%) were unaware of any guideline or policy governing the use of rFVIIa. Seventy percent of respondents would use the drug in their future practice. Deployed surgeons generally have positive attitudes regarding the use of rFVIIa, but greater guidance and outcome measures are needed.
Kembro
Ronald J
RJ
Department of Surgery, William Beaumont Army Medical Center, 5005 North Piedras Street, El Paso, TX 79920-5001, USA.
Horton
John D
JD
Wagner
Michel
M
D015942:Factor VIIa / Q000627:therapeutic use*; D013502:General Surgery; D019538:Health Care Surveys; D006291:Health Policy; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007493:Iraq; D054542:Iraq War, 2003-2011; D008887:Military Medicine; D008889:Military Personnel; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011994:Recombinant Proteins / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D014481:United States; D014947:Wounds and Injuries / Q000150:complications* / Q000503:physiopathology
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa